Hepatitis B and C diagnostics market to grow by $3.02b through 2028

Thanks to the emergence of immunosensors for HBV and HCV detection.

The global market for Hepatitis B and C diagnostics is projected to grow by $3.02b until 2028 at an estimated compound annual growth rate (CAGR) of 8.09%, said Technavio.

The sector’s expansion is attributed to the emergence of immunosensors for detecting HBV and HCV. These devices convert specific antibody-antigen interactions into measurable signals for rapid and accurate diagnosis. 

“Biosensor technology, including electrochemical, piezoelectric, acoustic, magnetic, and optical sensors, is extensively used for HCV RNA and anti-HCV detection,” the report said.

Moreover, nanotechnology poses a key market trend, with materials such as carbon nanotubes and nanofibers being employed as support materials for electrochemical immunosensors.

Meanwhile, rising demand for efficient and timely diagnostics and ongoing research initiatives are expected to further fuel the global market, with the increasing number of tests for these liver diseases a key growth factor.

Blood samples remain the primary source for diagnosing these conditions, employing methods such as molecular diagnostics, nucleic acid assays, and rapid diagnostic tests.

“Key technologies include enzyme-linked immunosorbent assay (ELISA), polymerase chain reaction (PCR), and imaging tests like liver biopsy,” the report added.